Advertisement
U.S. markets open in 8 hours 22 minutes

Oragenics, Inc. (OGEN)

NYSE American - NYSE American Delayed Price. Currency in USD
1.4100+0.0100 (+0.71%)
At close: 04:00PM EDT
1.3600 -0.05 (-3.55%)
After hours: 06:15PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close1.4000
Open1.4300
Bid0.0000 x 1000
Ask0.0000 x 800
Day's Range1.2600 - 1.4500
52 Week Range1.2600 - 7.7400
Volume217,127
Avg. Volume85,318
Market Cap6.318M
Beta (5Y Monthly)0.29
PE Ratio (TTM)N/A
EPS (TTM)-4.6000
Earnings DateApr 12, 2024 - Apr 16, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for OGEN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Oragenics Inc.
    Weekly Stock ListWe see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.
    Rating
    Fair Value
    Economic Moat
    18 hours agoArgus Research
View more
  • Business Wire

    Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

    SARASOTA, Fla., March 18, 2024--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. James "Jim" Kelly, Neurologist, as its Chief Medical Officer, to oversee its upcoming Phase II clinical trial. Oragenics’ lead drug candidate, ONP-002 is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (TBI), aka concussion. ONP-002 i

  • Insider Monkey

    15 Highest Quality Probiotics For Gut Health

    In this article, we will be taking a look at the 15 highest quality probiotics for gut health. If you do not want to learn about the global probiotic market, head straight to the 5 Highest Quality Probiotics For Gut Health. Achieving optimal gut health is paramount for overall well-being, and selecting the highest quality […]

  • Business Wire

    Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

    SARASOTA, Fla., March 05, 2024--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it is preparing to undertake the final steps of GMP manufacturing and formulation of its drug candidate for its expected Phase IIA clinical trial. The drug candidate is expected to be combined with its novel intranasal device, for the treatment of mild Traumatic Brain Injury, aka concussion. Oragenic